Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308773568> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- W4308773568 endingPage "251584142211345" @default.
- W4308773568 startingPage "251584142211345" @default.
- W4308773568 abstract "Neurotrophic keratopathy (NK) and limbal stem cell deficiency (LSCD) have high morbidity and require aggressive management to prevent permanent vision loss. Cenegermin, a recombinant human nerve growth factor, was approved by the Federal Drug Administration in 2018 for the treatment of NK.To determine the efficacy and safety of cenegermin in the treatment of LSCD associated with NK.Prospective cohort study.Patients diagnosed with LSCD and NK who had failed conventional treatment were enrolled in this prospective open-label study. Patients were treated with cenegermin for 8 weeks. The primary objective was to determine whether the area of abnormal epithelium decreased following treatment. Corneal sensation, visual acuity (VA), and LSCD severity were also evaluated.Six eyes of 5 patients were included in the study. Cenegermin significantly improved the area of abnormal corneal epithelium in 5 of 6 eyes, measuring 73% of total corneal area at the initial visit and 48% at the final visit (P = .036). Corneal sensation improved in all patients, Cochet-Bonnet aesthesiometry measured 14.7 and 26.7 mm at the initial and final visit, respectively (P = .009). VA improved in 4 out of 6 eyes, with mean initial logMAR VA of 1.67 and final logMAR VA of 1.19 (P = .045). Finally, LSCD grading improved using the Aravena scoring system; however, this difference was not statistically significant (P = .14). One patient presented with an epithelial defect at baseline, which resolved following treatment. No patient withdrew from the study due to adverse effects.Cenegermin effectively improved the cornea epithelium, VA, and corneal sensation in patients with LSCD and NK who had failed prior treatment. Further studies are necessary to better understand the anatomical changes and to confirm our results with a larger randomized control trial.The study was registered at ClinicalTrials.gov with identifier NCT04552730 (https://clinicaltrials.gov/ct2/show/NCT04552730)." @default.
- W4308773568 created "2022-11-15" @default.
- W4308773568 creator A5032823189 @default.
- W4308773568 creator A5062153204 @default.
- W4308773568 date "2022-01-01" @default.
- W4308773568 modified "2023-10-14" @default.
- W4308773568 title "Observational study of cenegermin for the treatment of limbal stem cell deficiency associated with neurotrophic keratopathy" @default.
- W4308773568 cites W2337729957 @default.
- W4308773568 cites W2787275688 @default.
- W4308773568 cites W2791911925 @default.
- W4308773568 cites W2797357911 @default.
- W4308773568 cites W2797681623 @default.
- W4308773568 cites W2893663323 @default.
- W4308773568 cites W2898101134 @default.
- W4308773568 cites W2970312470 @default.
- W4308773568 cites W2978090348 @default.
- W4308773568 cites W3023680900 @default.
- W4308773568 cites W3041016292 @default.
- W4308773568 cites W3100986163 @default.
- W4308773568 cites W3166110357 @default.
- W4308773568 cites W4211154256 @default.
- W4308773568 cites W4225694860 @default.
- W4308773568 doi "https://doi.org/10.1177/25158414221134598" @default.
- W4308773568 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36353571" @default.
- W4308773568 hasPublicationYear "2022" @default.
- W4308773568 type Work @default.
- W4308773568 citedByCount "0" @default.
- W4308773568 crossrefType "journal-article" @default.
- W4308773568 hasAuthorship W4308773568A5032823189 @default.
- W4308773568 hasAuthorship W4308773568A5062153204 @default.
- W4308773568 hasBestOaLocation W43087735681 @default.
- W4308773568 hasConcept C118487528 @default.
- W4308773568 hasConcept C126322002 @default.
- W4308773568 hasConcept C141071460 @default.
- W4308773568 hasConcept C188816634 @default.
- W4308773568 hasConcept C197934379 @default.
- W4308773568 hasConcept C2776882836 @default.
- W4308773568 hasConcept C2778257484 @default.
- W4308773568 hasConcept C2779257441 @default.
- W4308773568 hasConcept C71924100 @default.
- W4308773568 hasConceptScore W4308773568C118487528 @default.
- W4308773568 hasConceptScore W4308773568C126322002 @default.
- W4308773568 hasConceptScore W4308773568C141071460 @default.
- W4308773568 hasConceptScore W4308773568C188816634 @default.
- W4308773568 hasConceptScore W4308773568C197934379 @default.
- W4308773568 hasConceptScore W4308773568C2776882836 @default.
- W4308773568 hasConceptScore W4308773568C2778257484 @default.
- W4308773568 hasConceptScore W4308773568C2779257441 @default.
- W4308773568 hasConceptScore W4308773568C71924100 @default.
- W4308773568 hasFunder F4320306811 @default.
- W4308773568 hasFunder F4320337350 @default.
- W4308773568 hasLocation W43087735681 @default.
- W4308773568 hasLocation W43087735682 @default.
- W4308773568 hasLocation W43087735683 @default.
- W4308773568 hasLocation W43087735684 @default.
- W4308773568 hasOpenAccess W4308773568 @default.
- W4308773568 hasPrimaryLocation W43087735681 @default.
- W4308773568 hasRelatedWork W2001429827 @default.
- W4308773568 hasRelatedWork W2003938723 @default.
- W4308773568 hasRelatedWork W2047967234 @default.
- W4308773568 hasRelatedWork W2118496982 @default.
- W4308773568 hasRelatedWork W2360405837 @default.
- W4308773568 hasRelatedWork W2439875401 @default.
- W4308773568 hasRelatedWork W2568499524 @default.
- W4308773568 hasRelatedWork W3030423935 @default.
- W4308773568 hasRelatedWork W3043344165 @default.
- W4308773568 hasRelatedWork W38312103 @default.
- W4308773568 hasVolume "14" @default.
- W4308773568 isParatext "false" @default.
- W4308773568 isRetracted "false" @default.
- W4308773568 workType "article" @default.